All In Biotech

NDA 022221 · Thea Pharma

Akten

Lidocaine Hydrochloride · Ophthalmic

Last checked: Nov 20, 2026Latest source record: Nov 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Oct 7, 2008

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,569

373 Phase 3, 196 recruiting

FAERS reports

89

69 serious, 4 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 23, 2026.

1- INDICATIONS AND USAGE AKTEN is indicated for ocular surface anesthesia during ophthalmologic procedures in adults and pediatric patients. AKTEN is an amide local anesthetic indicated for ocular surface anesthesia during ophthalmologic procedures. ( 1 )

Mechanism: Lidocaine hydrochloride is an amide local anesthetic agent that stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. Anesthesia generally occurs between 20 seconds to 1 minute and persists for 5 to 30 minutes.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • AKTEN · LIDOCAINE HYDROCHLORIDE 3.5% · GEL, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Lidocaine" as an intervention, any sponsor and status, largest first.

All 2,569 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective14
  • local anaesthetic systemic toxicity8
  • off label use8
  • vision blurred8
  • visual acuity reduced8
  • overdose7
  • hypertension6
  • product use in unapproved indication6
  • eye pain5
  • visual impairment5
  • vitreous floaters5
  • cystoid macular oedema4

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20122
20134
20148
20151
20165
20181
20193
20202
20217
20224
202344
20243
20251
20264

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Akten (Lidocaine HCl/PF)

2024 spending

$2K

Beneficiaries

30

45 claims

Per beneficiary

$63

$17.44 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$1,901

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6,282 on PubMed

Sponsor: Thea Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.